Oligonucleotides, Antisense
"Oligonucleotides, Antisense" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.
MeSH Number(s)
D13.150.480
D13.444.600.150.640
D13.695.578.424.480
D27.720.470.530.600.150.640
Concept/Terms
Oligonucleotides, Antisense- Oligonucleotides, Antisense
- Antisense Oligonucleotides
- Anti-Sense Oligonucleotides
- Anti Sense Oligonucleotides
- Oligonucleotides, Anti-Sense
Below are MeSH descriptors whose meaning is more general than "Oligonucleotides, Antisense".
Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides, Antisense".
This graph shows the total number of publications written about "Oligonucleotides, Antisense" by people in Harvard Catalyst Profiles by year, and whether "Oligonucleotides, Antisense" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 6 | 8 |
1995 | 5 | 7 | 12 |
1996 | 9 | 6 | 15 |
1997 | 6 | 6 | 12 |
1998 | 8 | 2 | 10 |
1999 | 4 | 4 | 8 |
2000 | 4 | 9 | 13 |
2001 | 3 | 7 | 10 |
2002 | 3 | 9 | 12 |
2003 | 1 | 23 | 24 |
2004 | 4 | 8 | 12 |
2005 | 2 | 15 | 17 |
2006 | 2 | 9 | 11 |
2007 | 2 | 1 | 3 |
2008 | 0 | 4 | 4 |
2009 | 1 | 9 | 10 |
2010 | 0 | 6 | 6 |
2011 | 1 | 5 | 6 |
2012 | 3 | 6 | 9 |
2013 | 2 | 6 | 8 |
2014 | 4 | 4 | 8 |
2015 | 2 | 5 | 7 |
2016 | 4 | 6 | 10 |
2017 | 5 | 4 | 9 |
2018 | 7 | 3 | 10 |
2019 | 7 | 4 | 11 |
2020 | 7 | 7 | 14 |
2021 | 7 | 2 | 9 |
2022 | 5 | 5 | 10 |
2023 | 2 | 6 | 8 |
2024 | 1 | 2 | 3 |
Below are the most recent publications written about "Oligonucleotides, Antisense" by people in Profiles.
-
Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo. Nucleic Acids Res. 2024 May 22; 52(9):4799-4817.
-
Glis2 is an early effector of polycystin signaling and a target for therapy in polycystic kidney disease. Nat Commun. 2024 May 01; 15(1):3698.
-
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med. 2024 May 16; 390(19):1770-1780.
-
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial. Eur J Heart Fail. 2024 Mar; 26(3):674-682.
-
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3. J Clin Lipidol. 2024 Mar-Apr; 18(2):e261-e268.
-
Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice. Acta Neuropathol Commun. 2023 10 19; 11(1):166.
-
A single-cell map of antisense oligonucleotide activity in the brain. Nucleic Acids Res. 2023 08 11; 51(14):7109-7124.
-
A framework for individualized splice-switching oligonucleotide therapy. Nature. 2023 Jul; 619(7971):828-836.
-
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity. J Immunother Cancer. 2023 05; 11(5).
-
Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023 03 17; 379(6637):1140-1149.